Payment overview · 2025
General Payments
$274.71
15 reported records · 6 companies
Healthcare provider profile · identity verified
Trampas S Nolan, ARNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · PINEVILLE, KY · NPI 1033144191
Verified facts
What the public records show
CMS Open Payments records show Trampas S Nolan, ARNP received $274.71 in general payments during 2025 across 15 reported records.
ABBVIE INC. accounted for 32.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $89.55 | 32.6% | 5 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $69.03 | 25.1% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $49.62 | 18.1% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $28.54 | 10.4% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.35 | 7.4% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $17.62 | 6.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $274.71 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $89.55 | 5 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $69.03 | 3 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $42.28 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $28.54 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $20.35 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.62 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.26 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 111 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
103 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
111 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 416 | 42 |
| Gabapentin | Gabapentin | 296 | 29 |
| Omeprazole | Omeprazole | 256 | 49 |
| Atorvastatin Calcium | Atorvastatin Calcium | 240 | 43 |
| Levothyroxine Sodium | Levothyroxine Sodium | 227 | 39 |
| Lisinopril | Lisinopril | 190 | 39 |
| Alprazolam | Alprazolam | 170 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 157 | 25 |
| Amlodipine Besylate | Amlodipine Besylate | 147 | 31 |
| Losartan Potassium | Losartan Potassium | 124 | 23 |
| Montelukast Sodium | Montelukast Sodium | 120 | 23 |
| Mounjaro | Tirzepatide | 111 | 15 |
| Azithromycin | Azithromycin | 108 | 68 |
| Duloxetine Hcl | Duloxetine Hcl | 105 | 16 |
| Jardiance | Empagliflozin | 103 | 14 |
| Clonazepam | Clonazepam | 102 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 99 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 99 | 22 |
| Furosemide | Furosemide | 95 | 17 |
| Atenolol | Atenolol | 94 | 13 |
| Famotidine | Famotidine | 93 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 91 | 17 |
| Prednisone | Prednisone | 91 | 35 |
| Metformin Hcl | Metformin Hcl | 90 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 83 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 82 | 19 |
| Simvastatin | Simvastatin | 79 | 17 |
| Metoprolol Succinate | Metoprolol Succinate | 78 | 16 |
| Ibuprofen | Ibuprofen | 77 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 77 | 12 |
| Tramadol Hcl | Tramadol Hcl | 74 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 68 | 12 |
| Meloxicam | Meloxicam | 68 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 64 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 62 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 61 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 59 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 59 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 58 | suppressed |
| Lorazepam | Lorazepam | 57 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 52 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 49 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 48 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 48 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 48 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 43 | 21 |
| Trazodone Hcl | Trazodone Hcl | 43 | suppressed |
| Methocarbamol | Methocarbamol | 42 | suppressed |
| Ozempic | Semaglutide | 42 | suppressed |
| Valsartan | Valsartan | 42 | suppressed |
| Bupropion Xl | Bupropion Hcl | 41 | suppressed |
| Diazepam | Diazepam | 41 | suppressed |
| Glipizide Er | Glipizide | 41 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 40 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 37 | 11 |
| Eliquis | Apixaban | 35 | suppressed |
| Fluconazole | Fluconazole | 35 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | suppressed |
| Potassium Chloride | Potassium Chloride | 33 | suppressed |
| Spironolactone | Spironolactone | 33 | suppressed |
| Trulicity | Dulaglutide | 33 | suppressed |
| Carvedilol | Carvedilol | 32 | suppressed |
| Tradjenta | Linagliptin | 32 | suppressed |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 17 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Memantine Hcl | Memantine Hcl | 29 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 28 | suppressed |
| Allopurinol | Allopurinol | 26 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 15 |
| Topiramate | Topiramate | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Dexamethasone | Dexamethasone | 23 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Cilostazol | Cilostazol | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Nystatin | Nystatin | 17 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 13 |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $274.71 · 15 records | ABBVIE INC. | Auvelity, CAPLYTA, FANAPT, HETLIOZ, MOUNJARO, VRAYLAR, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error